论文部分内容阅读
美国德托纳比奇消息:一种新的雌激素受体(ER)测定能减少用无效激素治疗乳腺癌病人的数量。旧金山的肿瘤学家Christopher Benz在美国癌症协会(ACS)的专家讨论会上说,目前的受体测定对多达60％左右的病例不能提供准确的预后信息。 ER+结果经常不足以使医生和病人确信肿瘤将缓慢生长,并对激素治疗有效。事实上正相反,病人需采取更积极的治疗。Benz说,激素疗法对约50％的ER+妇女有效,结果病人肿瘤的黄体酮受体(PR)检验结果也为阳性,其有效率为70％至80％。而有一组妇女只40％对
USA, Daytona Beach News: A new estrogen receptor (ER) assay can reduce the number of patients with breast cancer treated with ineffective hormones. Christopher Benz, an oncologist at San Francisco, said at an expert meeting of the American Cancer Society (ACS) that current receptor assays cannot provide accurate prognostic information in as many as 60% of cases. The ER+ results are often insufficient to convince doctors and patients that the tumor will grow slowly and be effective in hormone therapy. In fact, on the contrary, patients need to take more active treatment. Benz said that hormone therapy is effective for about 50% of ER+ women, and as a result, the progesterone receptor (PR) test results for patients with tumors are also positive, with an effective rate of 70% to 80%. And there is only 40% of a group of women